FIELD: medicine.
SUBSTANCE: present invention refers to biotechnology and medicine. What is presented is a method for generating an antibody and its functional fragments against a tumour antigen expressed on the tumour surface resistant to at least one anti-tumour compound by applying ground homogenate, and/or suspension, and/or cell lysate originated from the same tumour for immunisation. There are also disclosed using the method according to the invention for producing the monoclonal antibodies and their functional fragments, the monoclonal antibodies produced by the method, nucleic acids coding them, an expression vector, a host cell, and a method for preparing the antibody with using them, as well as hybridomes secreting these antibodies and their functional fragments for preparing a drug, the anti-tumour composition and using it as a drug.
EFFECT: invention can find further application in therapy of resistant tumours.
42 cl, 7 dwg, 4 ex, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES SPECIFICALLY BINDING TYPE 1 RECEPTOR OF FIBROBLAST GROWTH FACTOR, ANTIBODIES APPLICATION FOR ONCOLOGICAL DISEASE TREATMENT, METHOD FOR ANTIBODIES PRODUCTION | 2015 |
|
RU2638457C2 |
| ANTIBODY BOUND WITH CARBONIC ANHYDRASE, AND USE THEREOF | 2017 |
|
RU2727682C1 |
| ANTI-CD40-ANTIBODIES AND METHODS OF APPLICATION | 2012 |
|
RU2609647C2 |
| USE OF CD 151 ANTIBODIES FOR TREATING CANCER | 2007 |
|
RU2464041C2 |
| ANTI-HER2 ANTIBODY AND CONJUGATE THEREOF | 2014 |
|
RU2656161C1 |
| ANTIBODIES SPECIFIC TO TUMOUR AND USE THEREOF | 2011 |
|
RU2595403C2 |
| HUMANIZED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1 | 2015 |
|
RU2611685C2 |
| ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER DIAGNOSIS | 2013 |
|
RU2661772C2 |
| NOVEL ANTIBODY FOR DIAGNOSIS AND/OR PROGNOSIS OF CANCER | 2011 |
|
RU2651513C2 |
| USING ANTI-CD40-ANTIBODIES | 2008 |
|
RU2491095C2 |
